Clinical trial
Study of Deferasirox for Treatment of Transfusional Iron Overload in…
NCT00110266 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00110266 |
|---|---|
| Title | Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients |
| Official title | An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Iron Overload |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 176 |
| Start date | Jul 25, 2005 |
| Primary completion | Mar 28, 2008 |
| Completion | Mar 28, 2008 |
| First posted | May 5, 2005 |
| Last update posted | Aug 16, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: